HSPA1A and breast carcinoma: The mechanism through which the drug combination of the HSP70 inhibitor and doxorubicin achieve anticancer activity in breast cancer cells is very complex, and whether other pathways or molecules (Mint3 or DNAJC12) are related to p53 need to be investigated.